PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Oveporexton→

Oveporexton PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
2460722-04-5
Molecular formula
C23H25F5N2O4S
Molecular weight
520.52 g/mol
Drug class
Selective orexin receptor 2 (OX2R) agonistwake-promoting agent
Mechanism of action
Directly activates orexin type 2 receptors (OX2R), restoring orexin signalling that is deficient in narcolepsy type 1. OX2R activation promotes wakefulness and supports regulation of sleep-wake states and cataplexy-related pathways.
Indications / reported uses
  • Treatment of narcolepsy type 1 (narcolepsy with cataplexy) in adults under the US ORZEYFUL product label (FDA approval August 5, 2026).

Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220860Orig1s000lbl.pdf · https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-first-drug-treat-full-range-narcolepsy-type-1-symptoms · https://www.takeda.com/newsroom/newsreleases/2026/orzeyful-approved-narcolepsy/

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Oveporexton PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Oveporexton Permitted Daily Exposure (PDE) report (the Oveporexton PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Oveporexton Occupational Exposure Limit (OEL) report (the Oveporexton OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.